Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Neoplasms 3210Carcinoma, Non-Small-Cell Lung 2721Breast Neoplasms 2547Colorectal Neoplasms 1454Prostatic Neoplasms 1303Neoplasm Metastasis 1292Multiple Myeloma 1109Melanoma 1101Ovarian Neoplasms 1001Lung Neoplasms 941Recurrence 921Leukemia, Myeloid, Acute 876Pancreatic Neoplasms 830Lymphoma, Non-Hodgkin 766Lymphoma 713Stomach Neoplasms 691Carcinoma, Renal Cell 658Carcinoma, Hepatocellular 645Leukemia, Lymphocytic, Chronic, B-Cell 560Squamous Cell Carcinoma of Head and Neck 546Lymphoma, Follicular 515Head and Neck Neoplasms 488Glioblastoma 472Small Cell Lung Carcinoma 444Lymphoma, Large B-Cell, Diffuse 440Triple Negative Breast Neoplasms 433Advanced Solid Tumors 430Leukemia 426Uterine Cervical Neoplasms 418Urinary Bladder Neoplasms 405

Interventions

pembrolizumab 1enfortumab vedotin 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × Muscle-invasive Bladder Cancer × Clear all
NCT07475806 2026-05-15

A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder

Astellas Pharma Inc

Phase 2 Recruiting
240 enrolled
Genitourinary

Muscle-invasive Bladder Cancer

NCT04660344 2026-03-27

IMvigor011

Hoffmann-La Roche

Phase 3 Active not recruiting
761 enrolled 1 FDA
Genitourinary

Muscle-invasive Bladder Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡